Scilex Holding Company Common Stock

SCLXNASDAQ • USD
2.33 USD
↘ 0.02 (0.85%)AT CLOSE (03:59 PM EDT)
2.19
↘ 0.14 (6.18%)
POST MARKET (AS OF 07:58 PM EDT)
Post Market
AS OF 07:58 PM EDT
2.19
↘ 0.14 (6.18%)
🔴Market: CLOSED

Scilex Holding Company Common Stock (SCLX) is currently trading at $2.35. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 1/9, exceptional Return on Equity (145.4%), a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Oct 26, 2026.

Open?$2.35
High?$2.40
Low?$2.28
Prev. Close?$2.35
Volume?47.8K
Avg. Volume?41.8K
VWAP?$2.34
Rel. Volume?1.14x
Bid / Ask
Bid?$2.19 × 100
Ask?$2.25 × 5.5K
Spread?$0.06
Midpoint?$2.22
Valuation & Ratios
Market Cap?16.4M
Shares Out?8.5M
Float?6.3M
Float %?74.1%
P/E Ratio?N/A
P/B Ratio?-0.05
EPS?-$63.73
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Employees
34
Market Cap
16.5M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2022-11-11
Address
960 SAN ANTONIO ROAD
PALO ALTO, CA 94303
Phone: (650) 516-4310
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
0
Momentum?
18
Short Sent.?
89
Piotroski F-Score?1/9Weak
Altman Z-Score?-12.74Distress
Confidence?46%Low
Full Fundamental Analysis →
Short InterestLow
Short % of Float?2.36%Low
Short Interest?148.4K
Days to Cover?2.6
Free Float6.3M
Avg Daily Volume56.4K
Settlement Date2026-10-15
Financial Health
Current Ratio?0.07Weak
Quick Ratio?0.06Weak
Cash Ratio?0.00Low
Debt/Equity?-0.27Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
92/100
P/E?
N/A▾
P/B?
S&P
97
-0.05CHEAP▾
P/S?
Peers
100
S&P
97
0.52CHEAP▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-0.4CHEAP▾
EV/Sales?
Peers
100
S&P
59
3.13FAIR▾
Returns & Efficiency
ROE?
Peers
50
S&P
97
145.4%STRONG▾
ROA?
S&P
3
-176.8%WEAK▾
Cash Flow & Enterprise
FCF?$-17811000
Enterprise Value?$98.9M
Fundamentals ratios updated end of day